Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Infect Dis Clin Pract (Baltim Md). Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
Infect Dis Clin Pract (Baltim Md). 2009 November; 17(6): 357–359.
doi:  10.1097/IPC.0b013e3181bf5fc2
PMCID: PMC2954418

The Interplay between Sexually Transmitted Infections and HIV: An Evolving Story

It is recognized that persons with sexually transmitted infections (STIs) are at increased risk for acquisition of HIV. Early studies primarily linked this association to high-risk sexual behaviors that placed persons at risk for both STIs and HIV. However, continuing research has elegantly revealed that independent of behavioral factors, the presence of an STI, especially ulcerative types (e.g., herpes simplex virus 2 (HSV-2), primary syphilis), appears to be associated with a higher risk for subsequent HIV acquisition [1, 2]. The mechanisms for this heightened risk include the disruption of the mucosal epithelial lining of the genital tract, together with the local recruitment and influx of immature dendritic and CD4 cells, as part of the local inflammatory process. These cells contain the CCR5 receptor, the primary target for the entry of HIV into the body.

Although the initial findings of increased acquisition focused on ulcerative STIs, recent evidence has demonstrated the importance of non-ulcerative STIs (e.g., gonorrhea, Chlamydia), as reviewed by Naresh et al. [3]. In addition to these traditional non-ulcerative STIs, data just released indicate that human papillomavirus (HPV) infections are also a risk factor for HIV acquisition among both heterosexual men and men who have sex with men (MSM), as described in studies done in South Africa [4] and the United States [5], respectively. Of note, multiple and “high-risk” HPV types appear to convey the highest risk [4, 5]. In addition to the heightened risk for HIV acquisition, the presence of an STI may increase the transmission of HIV from infected persons to their partners as the result of higher plasma HIV viral load and via disruption of the normal mucosal barriers, with elevated genital HIV viral load shedding at the site of the coexisting infection. Collectively, these data suggest that STIs have had a dramatic worldwide impact on the HIV epidemic through the interplay between STIs and the increased risk of HIV acquisition and transmission.

What should we do with these findings? Intuitively, it would seem that STI prevention and treatment programs should be implemented where needed and reinforced where ongoing in an effort to reduce the number of incident HIV infections. Several community-based studies - largely within Africa - have examined the impact of STI treatment on reducing the incidence of HIV infections. As described by Naresh et al. (Table 3) [3], to date, many of these studies have revealed surprisingly little to no benefit from such interventions [6]. Potential reasons for the lack of efficacy are explored by Naresh et al. including that STIs may play a smaller role in a more advanced HIV epidemic, that the antibiotic utilized in some studies had a suboptimal effect against many of the prevalent STIs in the community, and of course, the possibility that control of bacterial STIs may not be an effective means of preventing HIV-1 infection [3].

Of major interest is the possibility of suppressing HSV-2 as a method of reducing incident HIV infections, as HSV-2 is arguably the most prevalent ulcerative STI in the world. The importance of HSV-2 in HIV transmission was highlighted in a recent publication, which, using deterministic models, suggested that genital herpes has played a more important role than any other STI in driving HIV prevalence in Africa and may have accounted for >25% of new HIV infections in some countries [7].

Research has demonstrated that HSV-2 suppression (with acyclovir or valacyclovir) reduces the plasma and genital HIV RNA levels, key components of HIV transmission, as well as the occurrence of clinical lesions [811]. Given these supportive preliminary data suggesting that HSV-2 suppression may reduce HIV transmission [12], three published randomized clinical studies have since evaluated this strategy among HSV-2/HIV-1 positive persons and the subsequent HIV incidence rates among their partners. These studies have shown no significant benefit of anti-HSV-2 suppressive therapy in preventing HIV transmission [1315]. In addition, a recent investigation conducted by Celum et al. concluded that after studying 3,408 heterosexual HIV-discordant couples at 14 African sites, acyclovir at 400 mg twice daily had no appreciable benefit (rate of new HIV infections in the acyclovir and placebo groups were 2.8 vs. 1.8/100 person-years, respectively; HR 0.92, p=0.70) [16].

We now need to reflect upon the reasons why these clinical trials did not show benefit. Perhaps multiple interventions (including methods to more effectively reduce risky behavior and suppress HSV-2 in combination) are in order. Associations between HSV-2 and HIV may be driven by residual confounding of higher risk sexual behaviors, suggesting that these factors may need to be addressed concurrently in clinical trials. Perhaps the dose of acyclovir was inadequate. Whether higher doses of acyclovir or the use of valacyclovir would result in greater reductions in HIV RNA plasma and genital levels, and, in turn, significantly reduce HIV transmission, requires further study. Finally, HSV-2 suppression in the setting of a prevalent infection may not mechanistically work. A recent report suggested that HIV receptor-positive inflammatory cells may persist in the genital area after the resolution of HSV-2 reactivation and the healing of lesions, perhaps explaining the inability of anti-HSV-2 therapy to reduce HIV acquisition [17]. Careful consideration of all these methodological possibilities is critical in the planning of future trials. Also on the horizon is the possibility of an HSV-2 vaccine that could have a substantial population-level impact on HIV incident infections [18]; further efforts to develop an effective HSV-2 vaccine should be undertaken.

Important interactions between STIs and HIV may extend beyond the public health arena to the health of the individual HIV-infected person. There are several reasons to encourage HIV-infected persons to engage in safer sex practices to avoid acquiring STIs. As described by Naresh et al., the occurrence of STIs in this population may result in more severe clinical disease, multiple episodes of recurrence, and/or more treatment failures compared to immunocompetent hosts [3]. Additionally, acquisition of another STI during HIV infection may be associated with transient reductions in the CD4 cell counts and elevations in HIV RNA levels. Not only is this a public health concern, since this may increase the transmissibility of HIV (as plasma and genital viral load levels are major factors in HIV transmissibility) [19], but it may also impact the immunologic and virologic status of the individual. Several studies have shown that acute STIs, such as syphilis, lead to adverse effects on the CD4 counts and viral loads [2022]; whether these effects are simply transient or have a long-term impact (especially in the setting of repeated STIs on HIV progression) requires further study. The role of HSV-2 suppression on HIV disease progression among dually infected persons was examined in a 2009 study by Lingappa et al. [23]. In this investigation, which took place in Africa among HIV patients with a CD4>250 who were not receiving antiretroviral therapy, acyclovir reduced the rate of both CD4 decline and mortality [23]. For now, whether HIV-infected persons who already have a non-curable STI (e.g., HSV-2 or HPV) will benefit from strategies to suppress these viral co-infections requires further data and will likely be a major focus of future research. All in all, these data suggest that the avoidance of acquiring an STI (“Prevention in Positives”) benefits both HIV-infected persons and the public health arena.

What should we as clinicians do with current findings? We should continue to explore evidence-based methods to reduce the occurrence of STIs among both HIV-infected and uninfected persons in an attempt to reduce new HIV infections. We should educate the public and our patients on the important interrelatedness between the acquisition of STIs and HIV. Finally, we should use these data to promote efforts in reducing high-risk behaviors among all persons, including among individuals already infected with HIV. With these interventions and further studies on the bidirectional interactions between HIV and STIs, a future with fewer incident HIV infections and ultimately control of the HIV epidemic will hopefully be closer at hand.


Support for this work was provided by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072.


The content of this publication is the sole responsibility of the authors and does not necessarily reflect the views or policies of the NIH or the Department of Health and Human Services, the DoD or the Departments of the Army, Navy or Air Force. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government.

This work is original and has not been published elsewhere.


1. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006 Jan 2;20(1):73–83. [PubMed]
2. Kapiga SH, Sam NE, Bang H, et al. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J Infect Dis. 2007 May 1;195(9):1260–9. [PubMed]
3. Naresh A, Beigi R, Woc-Colburn L, et al. The bidirectional interactions of HIV-1 and sexually transmitted infections: a review. Infect Dis Clin Prac. 2009 in press.
4. Auvert B, Lissouba P, Cutler E, et al. Is genital human papillomavirus infection associated with HIV incidence?. Abstract TUAC202, presented at the 5th IAS Conference of HIV Pathogenesis, Treatment, and Prevention; July 19–22, 2009; Capetown, South Africa.
5. Chin-Hong PV, Husnik M, Cranston RD, et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS. 2009 Jun 1;23(9):1135–42. [PubMed]
6. Sangani P, Rutherford G, Wilkinson D. Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Database Syst Rev. 2004;(2):CD001220. [PubMed]
7. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One. 2008 May 21;3(5):e2230. [PMC free article] [PubMed]
8. Delany S, Mlaba N, Clayton T, et al. Impact of acyclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS. 2009 Feb 20;23(4):461–9. [PMC free article] [PubMed]
9. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis. 2008 Dec 15;198(12):1804–8. [PMC free article] [PubMed]
10. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007 Nov 15;196(10):1500–8. Epub 2007 Oct 31. [PubMed]
11. Zuckerman RA, Lucchetti A, Whittington WL, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS. 2009 Feb 20;23(4):479–83. [PMC free article] [PubMed]
12. Delany-Moretlwe S, Lingappa JR, Celum C. New Insights on Interactions Between HIV-1 and HSV-2. Curr Infect Dis Rep. 2009 Mar;11(2):135–42. [PubMed]
13. Celum C, Wald A, Hughes J, et al. HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Jun 21;371(9630):2109–19. [PMC free article] [PubMed]
14. Watson-Jones D, Weiss HA, Rusizoka M, et al. HSV trial team; Steering and Data Monitoring Committees. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008 Apr 10;358(15):1560–71. [PMC free article] [PubMed]
15. Cowan FM, Pascoe SJ, Barlow KL, et al. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect. 2008 Dec;84(7):548–53. [PubMed]
16. Celum C, Wald A, Lingappa J, et al. Twice-daily acyclovir to reduce HIV-1 transmission form HIV-1 / HSV-2 co-infected persons within HIV-1 serodiscordant couples: a randomized, double-blind, placebo-controlled trial. Abstract WELBC101, presented at the 5th IAS Conference of HIV Pathogenesis, Treatment, and Prevention; July 19–22, 2009; Capetown, South Africa.
17. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009 Aug;15(8):886–92. [PMC free article] [PubMed]
18. Freeman EE, White RG, Bakker R, et al. Population-level effect of potential HSV-2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine. 2009 Feb 5;27(6):940–6. Epub 2008 Dec 9. [PMC free article] [PubMed]
19. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000 Mar 30;342(13):921–9. [PubMed]
20. Palacios R, Jiménez-Oñate F, Aguilar M, et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):356–9. [PubMed]
21. Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS. 2004;18:2075–2079. [PubMed]
22. Kofoed K, Gerstoft J, Mathiesen LR, et al. Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis. 2006 Mar;33(3):143–8. [PubMed]
23. Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir delays HIV-1 disease progression among HIV-1 / HSV-2 dually-infected persons: a randomized trial Abstract WELBC102. Abstract TUAC202, presented at the 5th IAS Conference of HIV Pathogenesis, Treatment, and Prevention; July 19–22, 2009; Capetown, South Africa.